<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908763</url>
  </required_header>
  <id_info>
    <org_study_id>3rd-SYSU-I-Cure-4</org_study_id>
    <nct_id>NCT02908763</nct_id>
  </id_info>
  <brief_title>HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients</brief_title>
  <official_title>HBsAg Loss/Seroconversion in Low Replicative Chronic HBV Infection Patients With Low Level HBsAg Treated With Peginterferon Alpha</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huizhou Municipal Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital, Shunde China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Third People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Kunming Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yuebei People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HBsAg Loss/Seroconversion is uncommon in Low replicative chronic HBV infection patients. The
      purpose of this study is to investigate the ability of peginterferon alpha to achieve HBsAg
      loss/seroconversion therapy in Low replicative chronic HBV infection patients with Low Level
      HBsAg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low replicative chronic HBV infection patients with low Level HBsAg were enrolled in the
      out-patient department of 3rd Affiliated Hospital of Sun Yat-sen University. All of them were
      HBsAg positive and anti-HBs negative for more than 6 months with HBV DNA&lt;2000 IU/mL and HBsAg
      levels ≤1000 IU/mL. All patients did not have other liver diseases and contraindications for
      interferon therapy.

      After giving informed consent, patients were treated with weekly subcutaneous injections of
      alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week. The use of other
      immune suppressive or regulatory drugs and other antiviral drugs was prohibited during the
      course of the study.

      In this study, treatment endpoint was HBsAg loss(＜0.05 IU/mL) and anti-HBs positive(＞10
      milli-International unit(mIU)/mL) defined as seroconversion. Depending on the decline of
      HBsAg level, treatment was either continued for a prolonged period (no more than 96 weeks)
      until the endpoint was achieved, or terminated in case of nonresponse. Treatment was
      proceeded if HBsAg level continued to decline until HBsAg seroconversion was achieved and the
      anti-HBs level was above 200 mIU/ml. If the patients were not willing to extend treatment,
      the therapy was ended at the time of HBsAg loss, or stopped without further decline of HBsAg
      levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBsAg Clearance Rate</measure>
    <time_frame>96 weeks</time_frame>
    <description>Percentage of Participants with HBsAg negative.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBsAg Seroconversion Rate</measure>
    <time_frame>96 weeks</time_frame>
    <description>Percentage of Participants with HBsAg negative and anti-HBsAg positive</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Pegylated interferon group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low replicative chronic HBV infection patients with HBsAg &lt;1000 IU/ mL and HBV DNA&lt;2000 IU/mL are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for at most 96 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observing Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Only observing and following up in this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa</intervention_name>
    <description>peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.</description>
    <arm_group_label>Pegylated interferon group</arm_group_label>
    <other_name>peginterferon alfa-2a or peginterferon alfa-2b</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hepatitis B surface antigen (HBsAg) positive and &lt;1000 IU/mL.

          2. Hepatitis B surface antibody (HBsAb) negative.

          3. Hepatitis B e antigen (HBeAg) negative.

          4. Hepatitis B virus DNA &lt;2000 IU/mL.

          5. Absence of previous antiviral therapy.

        Exclusion Criteria:

          1. Patients with active alcohol and/or drugs consumption.

          2. Patients with liver cirrhosis, Hepatocellular Carcinoma or other malignancies.

          3. Patients with other factors causing liver diseases.

          4. Pregnant and lactating women.

          5. Patients with concomitant HIV infection or congenital immune deficiency diseases.

          6. Patients with diabetes, autoimmune diseases.

          7. Patients with important organ dysfunctions.

          8. Patients with mental illness.

          9. Patients who receive antineoplastic or immunomodulatory therapy in the past 12 months.

         10. Patients who can't come back to clinic for follow-up on schedule.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Infectious Diseases, The Third Affliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi-Liang Gao, Professor</last_name>
      <phone>86-20-85252373</phone>
      <email>zhilianggao@21cn.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiang Zhu, Doctor</last_name>
      <phone>86-20-85252372</phone>
      <email>0628zhuxiang@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhi-Liang Gao, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>May 20, 2018</last_update_submitted>
  <last_update_submitted_qc>May 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Zhiliang Gao</investigator_full_name>
    <investigator_title>chief director of department of infectious disease</investigator_title>
  </responsible_party>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>Peginterferon Alpha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

